Strong growth in CSL's influenza vaccine business and the successful integration of an iron deficiency therapy company helped Australia's third-biggest company beat earnings forecasts in the first half, despite flagging profit from its blood products division.
CSL said on Tuesday it made $US1.82 billion ($2.6b) in underlying net profit after tax for the six months to December 31, up 10 per cent from a year ago after adjusting for currency fluctuations.
It made $US7.6b ($19.9b) in revenue, up 25 per cent on a constant currency basis.
